New and Updated Topics and Pathways. Topics with new or revised pathways in this release include Cellular responses to stimuli (High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells, Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells, Mitochondrial unfolded protein response (mtUPR)), Disease (Disease of branched-chain amino acid catabolism), Gene Expression (Epigenetic regulation of gene expression by MLL3 and MLL4 complexes, Epigenetic regulation of adipogenesis genes by MLL3 and MLL4), Metabolism (Aflatoxin activation and detoxification, Arachidonate metabolism, Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives, Biosynthesis of specialized pro-resolving mediators (SPMs), Carnitine shuttle, Cobalamin (Cbl) metabolism, Endogenous sterols, Formation of the active cofactor, UDP-glucuronate, Glucocorticoid biosynthesis, Metabolism of nitric oxide: NOS3 activation and regulation, Peroxisomal lipid metabolism), and Metabolism of proteins (Proteasome assembly).
New and Updated Illustrations. New or revised Illustrations with embedded navigation features have been created for Cellular responses to mechanical stimuli, Cellular responses to stimuli, Cellular responses to stress, Diseases of Metabolism, Diseases of branched-chain amino acid catabolism, Maple Syrup Urine disease, Epigenetic regulation of gene expression, Post-translational protein modification, Response of endothelial cells to shear stress, and Toll-Like Receptors Cascades.
Thanks to our Contributors. David P Hill and Rui Xiao are our external reviewers.
Annotation Statistics. Reactome comprises 15,492 human reactions organized into 2,742 pathways involving 30,892 proteins and modified forms of proteins encoded by 11,289 different human genes, 15,299 complexes, 2,127 small molecules, and 1,057 drugs. These annotations are supported by 39,318 literature references. We have projected these reactions onto 79,857 orthologous proteins, creating 19,783 orthologous pathways in 14 non-human species. Version 90 has annotations for 4,943 protein variants (mutated proteins) and their post-translationally modified forms, derived from 391 proteins, which have contributed to the annotation of 1,808 disease-specific reactions and 746 pathways.
Tools and Data. Our services and software tools are designed for biologists, bioinformaticians, and software developers. Pathway data is available to view in our Pathway Browser, to analyze your own dataset, to download, and access programmatically through our Content and Analysis Services. The ReactomeFIViz app and ReactomeGSA package provide tools for multi-omics data analysis. The idg.reactome.org Web Portal provides a collection of web-based tools to help researchers place understudied proteins in a pathway context.
Documentation and Training. Visit our online User Guide to access documentation supporting pathway analysis of experimental data. The Developer's Zone provides detailed documentation regarding our software, tools, and web services. Training and learning materials can be found here.
About the Reactome Project. Reactome is a collaboration between groups at the Ontario Institute for Cancer Research, Oregon Health and Science University, New York University Langone Medical Center, and The EMBL - European Bioinformatics Institute. Reactome is an ELIXIR Core Data Resource as well as a Global Core Biodata Resource. Reactome annotation files and interaction data derived from Reactome are distributed under a Creative Commons Public Domain (CC0 1.0 Universal) Licence. A Creative Commons Attribution 4.0 International (CC BY 4.0) Licence applies to all software and code, database data dumps, and Pathway Illustrations (Enhanced High-Level Diagrams), Icon Library, Art, and Branding Materials. A full description of the new and updated content is available on the Reactome website.
Follow us on Twitter: @reactome to get frequent updates about new and updated pathways, feature updates, and more!
For more information: If you have a question, want to provide feedback, or are interested in collaborating with us to annotate a topic, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..
